The Sage Group

THE SAGE GROUP Announces that Mary L. Yost, President, Will Lecture at the NEW CARDIOVASCULAR HORIZONS (NCVH) Inaugural Economic Session “Understanding the Business of Peripheral Interventions”

BEAUFORT SC, May 12, 2015 (BUSINESS WIRE)—Ms. Yost’s lecture titled, “The Economic Cost of PAD, CLI and Venous Disease: How Big Is the Market?” will be delivered at the first annual New Cardiovascular Horizons (NCVH) economic conference on May 26, 2015. Part of the 16th annual NCVH meeting, this educational pre-event will be held from 1:00 pm-4:30 pm at The Roosevelt Waldorf-Astoria in New Orleans, Louisiana. Course Directors are Craig M. Walker, MD and Mary L. Yost, MBA.

“This is a unique and much needed educational offering,” Ms. Yost stated. “I do not believe that any other interventional conferences, or even the broader cardiovascular conferences, offer anything comparable. If the topic is even covered, typically all that is offered on the economics/costs of peripheral artery disease (PAD) and critical limb ischemia (CLI) has been one lecture for an entire meeting!”

“The program of ‘The Business of Peripheral Interventions’ was structured to provide a comprehensive review of the current economic, financial and reimbursement issues surrounding peripheral and venous disease,” continued Yost. “In contrast to coronary disease, little research has been published on costs and the economic impact of PAD and CLI or on the costs and consequences of the different treatment options. There is a significant unmet need for additional information and more research on all economic aspects of PAD. This meeting represents an important first step,” she explained.

According to THE SAGE GROUP, PAD is one of the most widespread chronic diseases. Currently afflicting almost 20 million U.S. citizens, PAD prevalence is exceeded only by diabetes and venous disease. Costing an estimated $200 to almost $400 billion, PAD direct disease costs exceed those of diabetes and coronary disease, well as all cancers combined.

“Despite the magnitude of the national bill, PAD remains underestimated, underdiagnosed, undertreated and under-researched, which results in unnecessary mortality, morbidity and amputations,” emphasized Yost.

“Because PAD is so prevalent and costly, physicians, hospital administrators, insurance companies and Medicare/Medicaid policy makers need to understand its significant macroeconomic impact, the relative costs and consequences of different treatment options (including amputation), as well as the costs and consequences of not diagnosing and treating the disease,” Yost stated.

Additional information and a detailed agenda for “The Business of PAD” can be found at:

For more information on NCVH, including the conference program, or to register, visit or contact (337) 993-7920 or

About NCVH

NCVH is an educational nonprofit foundation focused on multidisciplinary accredited conferences to advance the field of cardiovascular care using endovascular technologies, pharmacotherapy treatments, peripheral interventions and amputation prevention techniques. With a goal to empower healthcare providers with knowledge of head-to-toe vascular treatments, NCVH strives to promote interdisciplinary teamwork and collaboration to address the continuum of patient care.

Educational activities include an annual multi-day conference, fellows course and vein forum along with one-day regional meetings around the United States. Internationally, NCVH hosts an annual conference in Latin America and participates with focused educational sessions at various meetings in China. For a complete list of upcoming events, visit


THE SAGE GROUP, a research and consulting company, specializes in atherosclerotic and venous disease in the lower limbs, specifically PAD, CLI, intermittent claudication (IC) and ischemic diabetic foot ulcers (DFU). The most recent research focuses on quantifying the economic and social costs of PAD, CLI and amputation. For additional information visit


Mary Yost 404-520-6652